Loading...
Loading...
XGN| Name | Value |
|---|---|
| Revenues | 15.1M |
| Cost of Revenue | 6.0M |
| Gross Profit | 9.1M |
| Operating Expense | 11.6M |
| Operating I/L | -2.6M |
| Other Income/Expense | -0.4M |
| Interest Income | 0.2M |
| Pretax | -3.0M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -3.0M |
Exagen Inc. develops and commercializes testing products under the AVISE brand, catering to rheumatologists for the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases. Its lead product, AVISE CTD, aids in differential diagnosis for connective tissue diseases. The company also offers AVISE Lupus, APS, SLE Prognostic, Vasculitis AAV, Anti-CarP, and PC4d tests, along with biomarker blood tests and monitoring tests for specific medications. Exagen Inc. generates revenue through the sale of these testing products, which are based on its cell-bound complement activation products technology, providing valuable diagnostic and monitoring solutions for patients with autoimmune conditions.
